Clinical Trials Search
Clinical Trial 19070
Cancer Type: Malignant Hematology
Interventions:Axicabtagene Ciloleucel (KTE-C19); cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Study Type: Treatment
Phase of Study: NA
- Frederick Locke
A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Relapsed/Refractory Transplant-Ineligible Aggressive Non-Hodgkin Lymphoma (NHL)
The main purpose of this research study is to determine if the experimental product, KTE-C19, when administered after the participants receive a 3 day course of chemotherapy, is safe and effective in treating their disease.
The Primary Objective is to provide access of axicabtagene ciloleucel for subjects with relapsed/refractory aggressive NHL who are transplant ineligible until axicabtagene ciloleucel is commercially available in each respective participating country. Secondary Objectives are to describe the safety and efficacy of axicabtagene ciloleucel treatment.